Inclusion Criteria:  Diagnosis of ET, as defined by all of the following criteria:  Isolated tremor syndrome consisting of bilateral upper limb action tremor At least 3 years duration With or without tremor in other locations (eg, head, voice, or lower limbs) Absence of other neurological signs, such as dystonia, ataxia, or parkinsonism, isolated focal tremors (eg, voice, head), task- and position-specific tremors, sudden tremor onset, or evidence of stepwise deterioration of tremor Scores of at least 12 in the combined total upper limb TETRAS (total Performance Subscale Item 4) with the total score for the dominant upper limb (the sum of the three items for either the right or left upper limb, whichever is dominant) of at least 6, at both Screening and pre-dose on Day 1 Willing to discontinue medications taken for the treatment of ET at least 14 days or 5 half-lives (whichever is longer) prior to receiving investigational product (IP). Medications taken for the treatment of ET that were discontinued prior to receiving IP may be resumed following Day 97  Exclusion Criteria:  Presence of known causes of enhanced physiological tremor Recent exposure (14 days prior to Day 1) to tremorgenic drugs or presence of alcohol withdrawal state Direct or indirect injury or trauma to the nervous system within 3 months before the onset of tremor Previous procedure for the treatment of ET, deep brain stimulation, brain lesioning, or magnetic resonance (MR) guided procedure, eg, MR-guided focused ultrasound Historical or clinical evidence of tremor with psychogenic origin (including, but not limited to, eating disorders and major depression)